Literature DB >> 20378603

Cystic fibrosis and survival to 40 years: a case-control study.

N J Simmonds1, S J Macneill, P Cullinan, M E Hodson.   

Abstract

The clinical course of patients with cystic fibrosis (CF) is variable and probably determined by many interacting factors. We aimed to examine the influence of early social and clinical factors on long-term survival. A case-control study of adult CF patients was used to compare long-term survivors (aged ≥ 40 yrs) with patients who died before reaching 30 yrs of age. Each case (n = 78) was matched by birth date with at least one control (n = 152), after exclusion of "late diagnosis" patients. Probability-weighted logistic regression models were used to identify influences on survival. Factors resulting in increased probabilities of survival included high body mass index (OR 1.76, 95% CI 1.40-2.22), forced expiratory volume in 1 s (OR per 5% increase 1.54, 95% CI 1.32-1.80), and forced vital capacity (OR per 5% increase 1.54, 95% CI 1.33-1.78) at transfer to the adult clinic and the exclusive use of oral antibiotics (OR 8.31, 95% CI 3.02-22.88). Factors resulting in decreased probabilities of survival were Pseudomonas aeruginosa acquisition (OR 0.18, 95% 0.05-0.65) or pneumothorax before transfer to the adult clinic (OR 0.02, 95% CI 0.004-0.08) and referral from a paediatric clinic in a deprived area (OR 0.13, 95% CI 0.04-0.38). Long-term survival is associated with the clinical features present by the time of referral to an adult clinic. Even "early-diagnosis" disease appears to have different phenotypes, possibly independent of CF gene function, that have different survival patterns.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378603     DOI: 10.1183/09031936.00001710

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

1.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Authors:  Timothy J Bensman; Joshua Wang; Jordanna Jayne; Lynn Fukushima; Adupa P Rao; David Z D'Argenio; Paul M Beringer
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis.

Authors:  Marisa E Hilliard; Michelle N Eakin; Belinda Borrelli; Angela Green; Kristin A Riekert
Journal:  Health Psychol       Date:  2014-08-11       Impact factor: 4.267

Review 3.  Pneumothorax in cystic fibrosis.

Authors:  Ioannis P Kioumis; Konstantinos Zarogoulidis; Haidong Huang; Qiang Li; Georgios Dryllis; Georgia Pitsiou; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Antonis Papaiwannou; Sofia Lampaki; Konstantinos Porpodis; Bojan Zaric; Perin Branislav; Ioannis Mpoukovinas; George Lazaridis; Paul Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

4.  IL8 gene as modifier of cystic fibrosis: unraveling the factors which influence clinical variability.

Authors:  Larissa Lazzarini Furlan; Fernando Augusto Lima Marson; José Dirceu Ribeiro; Carmen Sílvia Bertuzzo; João Batista Salomão Junior; Dorotéia Rossi Silva Souza
Journal:  Hum Genet       Date:  2016-05-21       Impact factor: 4.132

Review 5.  Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.

Authors:  Luis J V Galietta
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

6.  Association between the IVS4G>T mutation in the TCF7L2 gene and susceptibility to diabetes in cystic fibrosis patients.

Authors:  Daniela Tenório Furgeri; Fernando Augusto de Lima Marson; Antonio Fernando Ribeiro; Carmen Silvia Bertuzzo
Journal:  BMC Res Notes       Date:  2012-10-10

Review 7.  Long-term safety and efficacy of tobramycin in the management of cystic fibrosis.

Authors:  Emma Vázquez-Espinosa; Rosa María Girón; Rosa Mar Gómez-Punter; Elena García-Castillo; Claudia Valenzuela; Carolina Cisneros; Enrique Zamora; F Javier García-Pérez; Julio Ancochea
Journal:  Ther Clin Risk Manag       Date:  2015-03-12       Impact factor: 2.423

8.  Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis.

Authors:  Fernando A L Marson; Carmen S Bertuzzo; Antônio F Ribeiro; José D Ribeiro
Journal:  BMC Pulm Med       Date:  2012-09-05       Impact factor: 3.317

9.  Polymorphisms in the glutathione pathway modulate cystic fibrosis severity: a cross-sectional study.

Authors:  Fernando Augusto de Lima Marson; Carmen Silvia Bertuzzo; Antonio Fernando Ribeiro; Jose Dirceu Ribeiro
Journal:  BMC Med Genet       Date:  2014-03-04       Impact factor: 2.103

10.  Evaluating outpatient transition clinics: a mixed-methods study protocol.

Authors:  Jane N T Sattoe; Mariëlle A C Peeters; Sander R Hilberink; Erwin Ista; AnneLoes van Staa
Journal:  BMJ Open       Date:  2016-08-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.